PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients

被引：3
|
作者：
Contreras, A.
Herrera, S.
Wang, T.
Mayer, I.
Forero, A.
Nanda, R.
Goetz, M.
Chang, J. C.
Pavlick, A. C.
Fuqua, S. A. W.
Gutierrez, C.
Hilsenbeck, S. G.
Li, M. M.
Osborne, C. K.
Schiff, R.
Rimawi, M. F.
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Vanderbilt Univ, Nashville, TN 37235 USA
[3] Univ Alabama Birmingham, Birmingham, AL USA
[4] Univ Chicago, Chicago, IL 60637 USA
[5] Mayo Clin, Rochester, MN USA
[6] Methodist Hosp, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2013年 / 73卷
关键词：
D O I：
10.1158/0008-5472.SABCS13-PD1-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD1-2
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
    Mothaffar F. Rimawi
    Carmine De Angelis
    Alejandro Contreras
    Fresia Pareja
    Felipe C. Geyer
    Kathleen A. Burke
    Sabrina Herrera
    Tao Wang
    Ingrid A. Mayer
    Andres Forero
    Rita Nanda
    Matthew P. Goetz
    Jenny C. Chang
    Ian E. Krop
    Antonio C. Wolff
    Anne C. Pavlick
    Suzanne A. W. Fuqua
    Carolina Gutierrez
    Susan G. Hilsenbeck
    Marilyn M. Li
    Britta Weigelt
    Jorge S. Reis-Filho
    C. Kent Osborne
    Rachel Schiff
    Breast Cancer Research and Treatment, 2018, 167 : 731 - 740
  • [2] Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
    Rimawi, Mothaffar F.
    De Angelis, Carmine
    Contreras, Alejandro
    Pareja, Fresia
    Geyer, Felipe C.
    Burke, Kathleen A.
    Herrera, Sabrina
    Wang, Tao
    Mayer, Ingrid A.
    Forero, Andres
    Nanda, Rita
    Goetz, Matthew P.
    Chang, Jenny C.
    Krop, Ian E.
    Wolff, Antonio C.
    Pavlick, Anne C.
    Fuqua, Suzanne A. W.
    Gutierrez, Carolina
    Hilsenbeck, Susan G.
    Li, Marilyn M.
    Weigelt, Britta
    Reis-Filho, Jorge S.
    Osborne, C. Kent
    Schiff, Rachel
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 167 (03) : 731 - 740
  • [3] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    Cizkova, M.
    Dujaric, M-E
    Lehmann-Che, J.
    Scott, V.
    Tembo, O.
    Asselain, B.
    Pierga, J-Y
    Marty, M.
    de Cremoux, P.
    Spyratos, F.
    Bieche, I.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1807 - 1809
  • [4] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
    M Cizkova
    M-E Dujaric
    J Lehmann-Che
    V Scott
    O Tembo
    B Asselain
    J-Y Pierga
    M Marty
    P de Cremoux
    F Spyratos
    I Bieche
    British Journal of Cancer, 2013, 108 : 1807 - 1809
  • [5] Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with neoadjuvant chemotherapy: Sequential analysis
    Seo, Y. -J.
    Yu, J. -H.
    Kim, S. -W.
    Lee, J. -E.
    Nam, S. -J.
    Cho, S. -Y.
    Cho, E. -Y.
    VIRCHOWS ARCHIV, 2017, 471 : S61 - S61
  • [6] PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Shi, Qiyun
    Xuhong, Juncheng
    Luo, Tao
    Ge, Jia
    Liu, Feng
    Lan, Yang
    Chen, Qingqiu
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Liang, Yan
    Wang, Minghao
    Hu, Ying
    Zhang, Yi
    Bian, Xiuwu
    Qi, Xiaowei
    Jiang, Jun
    BRITISH JOURNAL OF CANCER, 2023, 128 (01) : 121 - 129
  • [7] PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Qiyun Shi
    Juncheng Xuhong
    Tao Luo
    Jia Ge
    Feng Liu
    Yang Lan
    Qingqiu Chen
    Peng Tang
    Linjun Fan
    Li Chen
    Yan Liang
    Minghao Wang
    Ying Hu
    Yi Zhang
    Xiuwu Bian
    Xiaowei Qi
    Jun Jiang
    British Journal of Cancer, 2023, 128 : 121 - 129
  • [8] PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrum
    Goel, S.
    Krop, I. E.
    ANNALS OF ONCOLOGY, 2016, 27 (08) : 1368 - 1372
  • [9] PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
    Barbareschi, Mattia
    Cuorvo, Lucia Veronica
    Girlando, Salvatore
    Bragantini, Emma
    Eccher, Claudio
    Leonardi, Elena
    Ferro, Antonella
    Caldara, Alessia
    Triolo, Renza
    Cantaloni, Chiara
    Decarli, Nicola
    Galligioni, Enzo
    Dalla Palma, Paolo
    VIRCHOWS ARCHIV, 2012, 461 (02) : 129 - 139
  • [10] PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy
    Mattia Barbareschi
    Lucia Veronica Cuorvo
    Salvatore Girlando
    Emma Bragantini
    Claudio Eccher
    Elena Leonardi
    Antonella Ferro
    Alessia Caldara
    Renza Triolo
    Chiara Cantaloni
    Nicola Decarli
    Enzo Galligioni
    Paolo Dalla Palma
    Virchows Archiv, 2012, 461 : 129 - 139
12345